Defining Key Signaling Nodes and Therapeutic Biomarkers in <i>NF1</i> -Mutant Cancers

Abstract

This work demonstrates that mTORC1 and MEK are key therapeutic targets in NF1-mutant cancers and establishes a noninvasive biomarker of effective, combined target inhibition that can be evaluated in clinical trials.